MedStar Authors catalog › Details for: Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.
Normal view MARC view ISBD view

Combined Vascular Brachytherapy and Stenting for the Treatment of In-Stent Restenosis.

by Buchanan, Kyle; Chan, Rosanna; Chen, Yuefeng; Satler, Lowell F; Torguson, Rebecca; Waksman, Ron; Zhang, Cheng.
Citation: ; American Journal of Cardiology. 125(5):712-719, 2020 03 01..Journal: The American journal of cardiology.Published: ; 2020; ; ISSN: 0002-9149.Full author list: Buchanan KD; Chan RC; Chen Y; Satler LF; Torguson R; Waksman R; Zhang C.UI/PMID: 31889523.Subject(s): Aged | Treatment Outcome | Stents | Retrospective Studies | *Percutaneous Coronary Intervention/mt [Methods] | Middle Aged | Male | Humans | *Graft Occlusion, Vascular/th [Therapy] | Graft Occlusion, Vascular/co [Complications] | Female | *Drug-Eluting Stents | *Coronary Restenosis/th [Therapy] | Coronary Restenosis/co [Complications] | Combined Modality Therapy | Cohort Studies | *Brachytherapy/mt [Methods] | Angina, Unstable/th [Therapy] | Angina, Unstable/et [Etiology] | Angina, Stable/th [Therapy] | Angina, Stable/et [Etiology]Institution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: (Click here) Abbreviated citation: ; Am J Cardiol. 125(5):712-719, 2020 03 01.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library: 1999 - 2006.Abstract: In-stent restenosis (ISR) remains a therapeutic challenge in the current drug-eluting stent (DES) era. Vascular brachytherapy (VBT) is a therapeutic option for ISR, but data about the outcomes of combination therapy with VBT and stenting for ISR lesions are sparse. We retrospectively analyzed patients who presented with ISR at our institution from 2003 through 2017. Three treatment arms were compared: VBT alone, VBT plus bare-metal stent (BMS), and VBT plus DES. Clinical, procedural, and 1-year outcome data were collected. Follow-up was obtained by phone calls and clinic visits. The patient cohort included 461 patients (764 ISR lesions). Of these, 333 patients (533 lesions) were treated with VBT alone, 89 patients (158 lesions) with VBT plus BMS, and 39 patients (73 lesions) with VBT plus DES. There were no significant differences in baseline characteristics among the 3 groups except for more patients with a remote smoking history in the VBT plus BMS (43.8%) and VBT plus DES groups (56.4%), and more patients with history of peripheral vascular disease (39.5%) and congestive heart failure (27%) in the VBT plus DES group. The most common clinical presentation was unstable angina (64.6%). In the VBT plus DES group, 10.3% of patients presented with MI, versus 5.5% in the VBT alone group and 2.2% in the VBT plus BMS group. At 1-year follow-up, the VBT plus DES group had higher rates of target vessel revascularization-major adverse cardiovascular events (38.5%) than the VBT plus BMS (21.3%) and VBT alone (15.6%) groups (p=0.002). In conclusion, in patients with ISR, combination therapy with VBT and stenting at the same setup is associated with worse outcomes at 12 months and, if possible, should be avoided. Copyright (c) 2019 Elsevier Inc. All rights reserved.

Powered by Koha